stockrow
Monday 9 November 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLCBasic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- +64.7%
- Free cash flow
- +44.3%
Quarter to June 2026, against a year earlier
0.83
0.03
−3.49%
Follow BGLC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 0 | 0 | 11 | 13 | 11 | 10 | 10 | 7 | 3 | +66.2% | — | — | — | — | |
| Gross margin, % | — | — | 13.57 | 44.02 | 15.10 | 16.96 | 11.52 | 13.61 | 13.56 | 14.62 | 12.34 | +1.1 pt | ||||||
| EBT | — | — | 0 | 0 | 1 | 1 | 0 | (3) | (2) | (3) | (3) | n/m | ||||||
| EBT margin, % | — | — | 28.21 | (217.09) | 11.08 | 7.80 | (2.78) | (26.69) | (16.77) | (40.20) | (82.36) | (68.4) pt | ||||||
| Net income | — | — | 0 | 0 | 1 | 1 | 0 | (3) | (2) | (3) | (3) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.38 | 0.18 | 13.29 | 9.37 | 7.58 | 0.62 | 5.34 | 4.00 | 1.29 | +39.7% | |||||
| Earnings | — | — | 0.05 | (0.34) | 1.28 | 0.53 | (0.25) | (0.17) | (0.90) | (1.61) | (1.26) | n/m | ||||||
| Cash flow | — | — | (0.50) | (0.30) | 0.64 | 0.01 | 0.38 | (0.11) | (1.17) | (0.99) | (0.35) | +10.4% | ||||||
| Capex | — | — | (0.07) | (0.02) | 1.22 | 0.00 | (0.04) | (0.01) | (0.13) | (0.02) | 0.00 | (16.7%) | ||||||
| Free cash flow | — | — | (0.57) | (0.32) | 1.87 | 0.00 | 0.35 | (0.12) | (1.30) | (1.01) | (0.35) | +8.6% | ||||||
| Book value | — | — | 2.75 | 1.56 | 7.77 | 5.03 | 4.63 | 0.61 | 4.67 | 4.64 | 3.22 | +7.7% | ||||||
| Shares, m | — | — | 1 | 1 | 1 | 1 | 1 | 16 | 2 | 2 | 2 | +18.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 45.73 | 45.73 | 216.27 | 485.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 99.1 | |||||
| P/S | — | — | 9.90 | 9.90 | 20.77 | 27.28 | 15.82 | 8.48 | 0.52 | 0.99 | 0.64 | 11.7 | ||||||
| P/B | — | — | 43.42 | 43.42 | 35.52 | 50.77 | 25.94 | 8.58 | 0.60 | 0.85 | 0.26 | 26.1 | ||||||
| EV/Sales | — | — | 9.74 | 9.74 | 20.53 | 27.12 | 15.63 | 7.89 | 0.08 | 0.46 | (0.47) | 11.4 | ||||||
| EV/FCF | — | — | 193.78 | 193.78 | 146.27 | 60,406.65 | 343.33 | (39.08) | (0.31) | (1.81) | 1.72 | 7,655.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | 0 | 1 | 0 | 1 | (2) | (2) | (2) | (1) | +31.2% | |||||
| Capex | — | — | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | (1.0%) | ||||||
| Free cash flow | — | — | 0 | 0 | 2 | 0 | 0 | (2) | (2) | (2) | (1) | +29.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 1 | 1 | 5 | 5 | 4 | 6 | 5 | 5 | 4 | +21.9% | |||||
| Net debt | — | — | (1) | (1) | (3) | (2) | (2) | (6) | (4) | (4) | (3) | +19.0% | ||||||
| Shareholders’ equity | — | — | 2 | 1 | 7 | 7 | 7 | 10 | 8 | 9 | 8 | +28.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (17.10) | 19.29 | 7.63 | (3.89) | (26.11) | (14.64) | (30.32) | (28.38) | (30.3) pt | |||||
| ROIC | — | — | 11.53 | (55.87) | 20.36 | 13.02 | (4.00) | (43.47) | (24.93) | (40.51) | (37.16) | (52.0) pt | ||||||
| ROE | — | — | 0.00 | (18.64) | 28.11 | 10.86 | (5.14) | (32.21) | (17.78) | (35.24) | (33.66) | (35.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 9 | 9 | 13 | 6 | 18 | 21 | 6 | — | (6.5%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.01 | 1.27 | 1.03 | 1.82 | 0.54 | 0.45 | 1.24 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
BioNexus Gene Lab Corp. vs peers in Specialty Chemicals (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FEAM 5E Advanced Materials, Inc. | $93.8M | — (loss-making) | — | — | n/m | +17.79% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NTIC Northern Technologies International Corporation | $72.0M | — (loss-making) | 186× | +12.59% (above 0%: growing) | n/m | +327.52% (above 0%: growing) | 33.63% | 2.13% | Compare |
| CITR CitroTech Inc. | $58.7M | — (loss-making) | — (loss-making) | −59.18% (below 0%: shrinking) | n/m | −30.95% (below 0%: shrinking) | 3.21% | (1,244.78%) | Compare |
| LOOP Loop Industries, Inc. | $12.3M | — (loss-making) | — (loss-making) | −53.57% (below 0%: shrinking) | n/m | +52.28% (above 0%: growing) | 3.42% | (1,792.31%) | Compare |
| BON Bon Natural Life Limited | $9.1M | 0.9× | 4.5× | +20.95% (above 0%: growing) | −14.29% (below 0%: shrinking) | −260.38% (below 0%: shrinking) | 33.34% | 0.00% | Compare |
| SNES Senestech, Inc. | $6.3M | — (loss-making) | — (loss-making) | +23.20% (above 0%: growing) | n/m | −42.77% (below 0%: shrinking) | 73.64% | (241.82%) | Compare |
| YMAT J-Star Holding Co., Ltd | $4.9M | — | — | — | — | — | — | — | Compare |
| CNEY CN Energy Group. Inc. | $3.9M | 2.9× | 1.1× | −99.90% (below 0%: shrinking) | +33.33% (above 0%: growing) | −113.57% (below 0%: shrinking) | 3.28% | 0.00% | Compare |
| BGLC BioNexus Gene Lab Corp. | $2.5M | — (loss-making) | — | −96.63% (below 0%: shrinking) | n/m | +44.32% (above 0%: growing) | 17.06% | (342.78%) | |
| Median of peers | $10.7M | — | 4.5× | −20.49% | — | −30.95% | 3.42% | 0.00% |